FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Ten-Year Survivals of Right Thoracic vs Left Thoracic Approach for Esophageal Cancer. PMID 39293749 · Ann Thorac Surg · 2025-Mar The study is a randomized trial in human oncology with primary time-to-event endpoints, but it compares two surgical approaches (right vs. left thoracic) and does not involve a drug-containing intervention. The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials. PMID 39289120 · Urol Oncol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial. PMID 39271420 · Eur Urol · 2025-Mar The trial meets criteria for oncology, human, randomized, Phase III, time-to-event endpoint, and original result, but the intervention compares radiotherapy fractionation schedules (both with identical androgen suppression), not a drug-containing vs. non-drug or drug-containing intervention. Therefore, it is ineligible due to lack of a drug intervention. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). PMID 39243213 · J Neuroendocrinol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial. PMID 39221611 · Headache · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial. PMID 39182825 · J Card Fail · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Robotic-assisted versus conventional laparoscopic surgery for endometrial cancer: long-term results of a randomized controlled trial. PMID 39181495 · Am J Obstet Gynecol · 2025-Mar 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action. PMID 39019150 · J Invest Dermatol · 2025-Mar This is a secondary analysis of a Phase III RCT focusing on an adverse event mechanism, not the primary time-to-event efficacy report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial. PMID 38937329 · Eur J Health Econ · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Favorable Clinical Outcomes After Humeral Head Depressor Muscle Coactivation Training With EMG for Patients With Arthroscopic Rotator Cuff Repair: A Randomized Controlled Trial. PMID 38499998 · Sports Health · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of concurrent radiotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized controlled trial. PMID 40672085 · J Gastrointest Oncol · 2025-Jun-30 The trial is an oncology RCT with drug intervention and time-to-event endpoints (OS, PFS), but the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The deterministic review code 'phase3_evidence_unclear' indicates uncertainty. Without explicit phase information, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy in patients with resectable gastric cancer: prospective randomized trial (PECORINO). PMID 40672074 · J Gastrointest Oncol · 2025-Jun-30 The study is a randomized, drug-intervention trial in oncology with a time-to-event secondary endpoint (PFS) and original results. However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata, and the primary endpoint is treatment adherence, not an efficacy endpoint as required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study. PMID 40642487 · Chin J Cancer Res · 2025-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of mailed surveillance invitations and telephone patient navigation to improve hepatocellular carcinoma surveillance uptake: study protocol of VIGILANT-a single-centre, two-arm randomised controlled trial. PMID 40588390 · BMJ Open · 2025-Jun-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A mobile supportive care app for patients with metastatic lung cancer: the Lung Cancer App (LuCApp) randomized controlled trial. PMID 40586961 · Support Care Cancer · 2025-Jun-30 The study is a randomized trial in oncology with a time-to-event endpoint, but it does not involve a drug-containing intervention (it tests a mobile app for symptom monitoring) and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial. PMID 39817409 · Nephrol Dial Transplant · 2025-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial. PMID 40579605 · Cancer Chemother Pharmacol · 2025-Jun-28 The abstract describes a randomized trial in metastatic breast cancer with a drug intervention (metformin + chemotherapy) and reports original results. However, it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) or Kaplan-Meier analysis. The primary outcome appears to be IGF-1 level changes, and the secondary outcome is disease progression (a binary outcome), not a time-to-event endpoint. Therefore, it does not meet the key criterion for inclusion in an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. PMID 40562048 · Lancet · 2025-Jun-28 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. PMID 40562047 · Lancet · 2025-Jun-28 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine. PMID 40577471 · Sci Adv · 2025-Jun-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer. PMID 40571867 · J Gastrointest Cancer · 2025-Jun-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Chemotherapy for Gastric Cancer may Worsen Prognosis in Elderly Women: Retrospective Analysis of Individual Patient Data from the CLASSIC Study. PMID 40571773 · J Gastrointest Cancer · 2025-Jun-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Selective neoadjuvant therapy of rectal cancer patients (SELREC): study protocol for a European randomised controlled, open, multicentre non-inferiority trial. PMID 40578870 · BMJ Open · 2025-Jun-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of the GRACE risk score according to troponin elevation in patients admitted with non-ST elevation acute coronary syndrome: a post hoc analysis of the UKGRIS parallel group cluster randomised controlled trial. PMID 40571489 · Open Heart · 2025-Jun-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation. PMID 40162661 · N Engl J Med · 2025-Jun-26 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Development and validation of critical appraisal tool for individual participant data meta-analysis: protocol for a modified e-Delphi study. PMID 40562555 · BMJ Open · 2025-Jun-25 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| [A 30-year review of gastric cancer surgery: China has achieved leapfrog leadership]. PMID 40550663 · Zhonghua Wei Chang Wai Ke Za Zhi · 2025-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| [Effect of side-to-end anastomosis on postoperative bowel function in rectal cancer surgery: a prospective single-center randomized controlled trial]. PMID 40550657 · Zhonghua Wei Chang Wai Ke Za Zhi · 2025-Jun-25 The study is a randomized Phase III trial in human oncology (rectal cancer) with primary results. However, it is ineligible because the intervention is a surgical technique comparison (not a drug-containing intervention), and the primary endpoint is a quality-of-life/functional outcome (LARS score), not a time-to-event efficacy endpoint as defined by the criteria (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analysis of such). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. PMID 40553148 · Am J Gastroenterol · 2025-Jun-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial. PMID 40391436 · Circulation · 2025-Jun-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Extended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial. PMID 40294395 · JAMA · 2025-Jun-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi. PMID 40106688 · Blood Adv · 2025-Jun-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. PMID 40551254 · Breast Cancer Res · 2025-Jun-23 The study meets oncology, human, randomized, time-to-event, drug intervention, and original result criteria. However, the phase of the trial (III/IIIb or II/III) is not explicitly confirmed in the provided metadata or abstract text. The abstract references a trial registration (NCT01042379) but does not specify the phase. Therefore, the 'phase3_or_definitive' criterion cannot be established, and the record is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prophylactic endoscopic pylorus dilatation prior to esophagectomy for esophageal cancer to prevent delayed gastric emptying, study protocol for a placebo-controlled randomized trial (PROPPER trial). PMID 40551220 · Trials · 2025-Jun-23 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review. PMID 40550923 · J Cancer Res Clin Oncol · 2025-Jun-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Remote ischaemic preconditioning in cemented hip arthroplasty (the PRINCIPAL study)-randomised controlled trial: study protocol. PMID 40550717 · BMJ Open · 2025-Jun-23 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The distal nephron biomarkers associate with diabetic kidney disease progression. PMID 40548378 · JCI Insight · 2025-Jun-23 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. PMID 40473450 · Lancet · 2025-Jun-21 The study is an oncology-related, randomized, phase 3 trial with a drug intervention and original results. However, it is excluded because the primary efficacy endpoint is objective response rate, not a time-to-event endpoint (such as OS, PFS, DFS, EFS, RFS, TTP) or analysis involving Kaplan-Meier curves or hazard ratios, which are required for inclusion in this Kaplan-Meier digitization cohort. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small-cell lung cancer better preserves white matter networks compared to conventional PCI. PMID 39718983 · Neuro Oncol · 2025-Jun-21 This is an original randomized phase 3 trial in oncology, but it evaluates radiation techniques (HA-PCI vs PCI) and reports on neurocognitive and imaging endpoints, not a drug intervention or a time-to-event efficacy endpoint (OS, PFS, etc.). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C]. PMID 40660986 · Zhonghua Gan Zang Bing Za Zhi · 2025-Jun-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| [Phrenic Nerve Cryotherapy for Preventing Prolonged Air Leak During VATS Lobectomy]. PMID 40640090 · Zhongguo Fei Ai Za Zhi · 2025-Jun-20 The study is a randomized trial in oncology (lung cancer) but fails key eligibility criteria: it is not a Phase III/IIIb or Phase II/III drug trial (the intervention is a procedural cryotherapy during surgery, not a drug), and it does not report a time-to-event efficacy endpoint (primary outcome is complication rate, not survival or progression). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial. PMID 40367400 · J Clin Oncol · 2025-Jun-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. PMID 40354592 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. PMID 40334149 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial. PMID 40294349 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study. PMID 40112876 · Br J Dermatol · 2025-Jun-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. PMID 39862230 · Br J Dermatol · 2025-Jun-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients. PMID 40573987 · Vaccines (Basel) · 2025-Jun-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Multicentre, Double-Blind, Randomised, Non-Inferiority Trial of a Novel Single-Injection Intra-Articular HMDA-Cross-Linked Hyaluronate Gel for Knee Osteoarthritis. PMID 40566128 · J Clin Med · 2025-Jun-19 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial. PMID 40537275 · RMD Open · 2025-Jun-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |